Get the Stockscreener App
16.21
1.06%
0.17
After Hours:
15.89
-0.32
-1.97%
Roivant Sciences Ltd stock is traded at $16.21, with a volume of 3.49M.
It is up +1.06% in the last 24 hours and up +15.13% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$16.04
Open:
$16.17
24h Volume:
3.49M
Relative Volume:
0.55
Market Cap:
$11.07B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
2.869
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-0.31%
1M Performance:
+15.13%
6M Performance:
+64.40%
1Y Performance:
+36.22%
1-Day Range:
$15.99
$16.28
1-Week Range:
$15.25
$16.40
52-Week Range:
$8.73
$16.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
16.21 | 10.95B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
A Look at Roivant Sciences’s Valuation Following Positive Phase 3 Result for Brepocitinib - simplywall.st
Top chart patterns to watch in Roivant Sciences Ltd.Trade Performance Summary & Community Verified Watchlist Alerts - newser.com
Evaluating Roivant Sciences Ltd. with trendline analysisQuarterly Portfolio Review & Fast Gaining Stock Reports - newser.com
Key metrics from Roivant Sciences Ltd.’s quarterly dataMarket Trend Summary & Free Weekly Watchlist of Top Performers - newser.com
What MACD and RSI say about Roivant Sciences Ltd.Trade Entry Summary & Weekly Watchlist of Top Performers - newser.com
How sentiment analysis helps forecast Roivant Sciences Ltd.Market Trend Report & Fast Moving Stock Trade Plans - newser.com
Using Bollinger Bands to evaluate Roivant Sciences Ltd.July 2025 Trends & Community Consensus Picks - newser.com
Is a relief rally coming for Roivant Sciences Ltd. holders2025 Bull vs Bear & Daily Oversold Bounce Ideas - newser.com
Combining machine learning predictions for Roivant Sciences Ltd.July 2025 Decliners & Reliable Volume Spike Trade Alerts - newser.com
Price action breakdown for Roivant Sciences Ltd.2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
Will earnings trigger a reversal in Roivant Sciences Ltd.Weekly Market Summary & Safe Entry Zone Identification - newser.com
Eric Venker Sells 355,161 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Eric Venker Sells 171,396 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Eric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
What earnings revisions data tells us about Roivant Sciences Ltd.Bear Alert & Comprehensive Market Scan Reports - newser.com
Is Roivant Sciences Ltd. (87S) stock undervalued historicallyPortfolio Risk Report & Real-Time Stock Entry Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D+)" Rating for Roivant Sciences (NASDAQ:ROIV) - MarketBeat
Can Roivant Sciences Ltd. stock deliver consistent earnings growthPortfolio Value Report & Growth Focused Entry Reports - newser.com
Roivant Sciences Hits New 52-Week High at $16.19, Up 52.84% - Markets Mojo
Roivant Sciences Hits New 52-Week High at $16.79, Surges 53.69% - Markets Mojo
Roivant Sciences’ president Venker sells $10.7m in shares - Investing.com
Valeo Financial Advisors LLC Buys Shares of 101,576 Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Rises on Nasdaq Composite with Strong Momentum - Kalkine Media
Roivant Sciences (NASDAQ:ROIV) Sets New 12-Month HighShould You Buy? - MarketBeat
Can you recover from losses in Roivant Sciences Ltd.2025 Price Action Summary & High Return Trade Guides - newser.com
What sentiment indicators say about Roivant Sciences Ltd. stockWeekly Trading Summary & Community Driven Trade Alerts - newser.com
Will Roivant Sciences Ltd. (87S) stock outperform value peersRisk Management & Consistent Profit Alerts - newser.com
Why Roivant Sciences (ROIV) Is Up 6.6% After Positive Phase 3 Brepocitinib Results and SEC Filing - simplywall.st
Why Roivant Sciences Ltd. (87S) stock attracts wealthy investorsTrade Risk Report & Fast Entry High Yield Stock Tips - newser.com
Will Roivant Sciences Ltd. continue its uptrendWeekly Investment Summary & Safe Capital Growth Tips - newser.com
Pattern recognition hints at Roivant Sciences Ltd. upsideMarket Growth Report & Safe Capital Growth Tips - newser.com
Why retail investors pile into Roivant Sciences Ltd. stock2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Is Roivant Sciences Ltd. stock reversal real or fakeM&A Rumor & High Win Rate Trade Tips - newser.com
Can Roivant Sciences Ltd. (87S) stock double in coming yearsJuly 2025 Breakouts & Fast Entry Momentum Alerts - newser.com
Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints - Insider Monkey
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades - Yahoo Finance
Elevate Capital Advisors LLC Sells 61,368 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) files mixed shelf - StreetInsider
Roivant Sciences (ROIV): Assessing Valuation Following Positive Phase 3 Results and Analyst Optimism - simplywall.st
Roivant Sciences Ltd. $ROIV Shares Purchased by GAMMA Investing LLC - Defense World
Fifth Third Bancorp Sells 1,829 Shares of Roivant Sciences Ltd. $ROIV - Defense World
Long term hold vs stop loss in Roivant Sciences Ltd.July 2025 Closing Moves & High Return Stock Watch Alerts - newser.com
Roivant Sciences Ltd.’s volatility index tracking explainedWeekly Trend Recap & Expert Curated Trade Setup Alerts - newser.com
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Oct 07 '25 |
Option Exercise |
7.21 |
355,161 |
2,559,093 |
1,860,120 |
| Venker Eric | President & Immunovant CEO |
Oct 06 '25 |
Option Exercise |
13.29 |
171,396 |
2,277,775 |
1,676,355 |
| Venker Eric | President & Immunovant CEO |
Oct 08 '25 |
Option Exercise |
8.07 |
138,602 |
1,119,164 |
1,643,561 |
| Venker Eric | President & Immunovant CEO |
Oct 07 '25 |
Sale |
16.15 |
355,161 |
5,735,850 |
1,504,959 |
| Venker Eric | President & Immunovant CEO |
Oct 06 '25 |
Sale |
16.34 |
171,396 |
2,800,611 |
1,504,959 |
| Venker Eric | President & Immunovant CEO |
Oct 08 '25 |
Sale |
16.20 |
138,602 |
2,245,352 |
1,504,959 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):